NCT01836068 is a EARLY_PHASE1 clinical trial of Enfuvirtide in HIV, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Who is sponsoring NCT01836068?

NCT01836068 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What drugs are being tested in NCT01836068?

Interventions in NCT01836068: Enfuvirtide.

Is NCT01836068 still recruiting?

NCT01836068 is currently completed. Last updated 22 November 2021.

Last reviewed 2021-11-22 · How we verify

NCT01836068

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1-infected Individuals

Completed EARLY_PHASE1 Last updated 22 November 2021

What this trial tests

EARLY_PHASE1 trial testing Enfuvirtide in HIV in 11 participants. Completed in 5 June 2021.

Timeline

1 June 2013

Primary endpoint
22 January 2020

5 June 2021

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	11
Start date	1 June 2013
Primary completion	22 January 2020
Estimated completion	5 June 2021
Sites	1 location across United States

Drugs / interventions tested

Enfuvirtide (ENFUVIRTIDE) — full drug profile →

Conditions studied

HIV — all drugs for HIV →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →

Who can join

18 and older, any sex, with HIV. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Determine the feasibility of maintaining optimal ART in HIV-1 infected patients during allogeneic HSCT
Time frame: 24 hours
Failure to maintain anti retroviral therapy for 24 hours

Sponsor's own description

To find out if it is possible for HIV-1 patients to maintain antiretroviral medications during allogeneic bone marrow transplant

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study.
Durand CM, Capoferri AA, Redd AD, Zahurak M, et al · · 2020 · cited 12× · PMID 32649866 · DOI 10.1016/s2352-3018(20)30073-4
Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials.
Bender Ignacio RA, Lin LL, Rajdev L, Chiao E. · · 2018 · cited 9× · PMID 30099376 · DOI 10.6004/jnccn.2018.7064
Brief Report: Rebound HIV Viremia With Meningoencephalitis After Antiretroviral Therapy Interruption After Allogeneic Bone Marrow Transplant.
Capoferri AA, Redd AD, Gocke CD, Clark LR, et al · · 2022 · cited 4× · PMID 34753870 · DOI 10.1097/qai.0000000000002862
Short Communication: Persistence of HIV After Allogeneic Bone Marrow Transplant in a Dually Infected Individual.
Capoferri AA, Redd AD, Gocke CD, Clark LR, et al · · 2022 · PMID 34107771 · DOI 10.1089/aid.2021.0047

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials

Trials by the same sponsor.

NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01836068 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 22 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01836068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing